Viehbacher Christopher
SEC CIK 1774478 · EDGAR
BoughtSold
Most active insiders at BRVE, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Forbion Growth Opportunities Fund III Cooperatief U.A. | 10% | $64.80M | — |
| 2 | Chimovits Erez | Dir, 10% | $34.92M | — |
| 3 | ORBIMED ADVISORS LLC | Dir, 10% | $34.92M | — |
| 4 | AH Bio Fund IV, L.P. | 10% | $19.80M | — |
| 5 | Murdoch Travis | CEO, Pres, Dir | $1.50M | — |
| 6 | Viehbacher Christopher | Dir | $1.50M | — |
| 7 | Lubner David Charles | Dir | $1000.0K | — |
| 8 | Rickey James Paul | CFO | $500.0K | — |
| 9 | Malek David I | Dir | $75.0K | — |
| 10 | Anderson Michele A. | Chief Development Off | $20.0K | — |
Transactions 7
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-08-07 16:31 | 2026-08-07 | BRVE | Braveheart Bio, Inc. | Viehbacher Christopher | Dir | P - Purchase | $18.00 | +83.3K | 609.5K | +16% | +$1.50M |
| DM | 2026-02-10 | 2026-02-06 | BIIB | Biogen | Viehbacher Christopher | Pres, CEO, Dir | M - OptEx | $0.00 | +24.5K | 36.5K | +202% | $0 |
| DM | 2026-02-10 | 2026-02-06 | BIIB | Biogen | Viehbacher Christopher | Pres, CEO, Dir | F - Tax | $201.18 | -11.0K | 21.1K | -34% | -$2.21M |
| D | 2025-12-03 | 2025-12-01 | BIIB | Biogen | Viehbacher Christopher | Pres, CEO, Dir | M - OptEx | $0.00 | +7,040 | 19.8K | +55% | $0 |
| D | 2025-12-03 | 2025-12-01 | BIIB | Biogen | Viehbacher Christopher | Pres, CEO, Dir | F - Tax | $177.78 | -3,404 | 16.4K | -17% | -$605.2K |
| D | 2025-02-10 | 2025-02-07 | BIIB | Biogen | Viehbacher Christopher | Pres, CEO, Dir | F - Tax | $141.35 | -3,201 | 12.8K | -20% | -$452.5K |
| D | 2025-02-10 | 2025-02-07 | BIIB | Biogen | Viehbacher Christopher | Pres, CEO, Dir | M - OptEx | $0.00 | +9,008 | 16.0K | +129% | $0 |
Purchase Sale Sale after option exercise All abbreviations